Olema Oncology CEO to Present at TD Cowen Health Care Conference
Event summary
- Olema Oncology CEO Sean P. Bohen to present at TD Cowen 46th Annual Health Care Conference on March 3, 2026.
- Presentation scheduled for 2:30 p.m. ET, with live webcast and recording available on Olema’s investor relations website.
- Olema’s lead product candidate, palazestrant (OP-1250), is in two Phase 3 clinical trials.
- Company also developing OP-3136, a KAT6 inhibitor, currently in Phase 1 clinical study.
The big picture
Olema Oncology’s participation in the TD Cowen Health Care Conference underscores its focus on advancing targeted therapies for breast cancer. The company’s pipeline, including palazestrant and OP-3136, positions it within the competitive landscape of endocrine-driven cancer treatments. The strategic emphasis on nuclear receptors and resistance mechanisms aligns with broader industry trends toward precision oncology.
What we're watching
- Clinical Progress
- How the Phase 3 trial results for palazestrant will impact Olema’s valuation and strategic positioning.
- Market Positioning
- Whether Olema can differentiate itself in the competitive breast cancer therapy market.
- Investor Sentiment
- The pace at which investor confidence will be influenced by upcoming clinical milestones.
Related topics